Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Advances in the treatment of Raynaud s phenomenon Levien TLVasc Health Risk Manag 2010[Mar]; 6 (ä): 167-77Raynaud's phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.|Antioxidants/therapeutic use[MESH]|Bosentan[MESH]|Botulinum Toxins, Type A/therapeutic use[MESH]|Calcium Channel Blockers/therapeutic use[MESH]|Endothelin Receptor Antagonists[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use[MESH]|Iloprost/therapeutic use[MESH]|Phosphodiesterase 5 Inhibitors/therapeutic use[MESH]|Raynaud Disease/*drug therapy[MESH]|Selective Serotonin Reuptake Inhibitors/therapeutic use[MESH]|Serotonin Antagonists/therapeutic use[MESH]|Sulfonamides/therapeutic use[MESH]|Vasodilator Agents/therapeutic use[MESH] |